Care · Understanding ZTTK
What Is ZTTK Syndrome?
A rare genetic condition caused by a change in a single gene — and the reason this community exists. Here is what it means, in plain language.
- SONOne gene, on chromosome 21
- 2016The year ZTTK was named
- ~500Known patients worldwide
- De novoAlmost always new in the child, not inherited
The Short Version
ZTTK syndrome (Zhu–Tokita–Takenouchi–Kim syndrome) is a rare genetic condition. It happens when a random change in a single gene — called SON — means a child's cells can't make enough of one important protein. That shortage affects how the brain and body develop.
Children with ZTTK typically have developmental delays, learning differences, and low muscle tone; many also have seizures, vision differences, or feeding difficulties. In almost every known case the change is de novo — new in the child rather than inherited — and not caused by anything a parent did.
ZTTK was only given a name in 2016, so every family here is a pioneer. This page walks through the genetics, the features doctors watch for, how diagnosis works, and where the science is heading — no medical degree required.
The Genetics, Explained Simply
Understanding ZTTK starts with one gene and a simple idea: for one important protein, having only half the usual amount isn’t enough.
It starts with one gene
Deep inside every cell, chromosome 21 carries a gene called SON. A gene is a set of instructions — SON’s instructions tell the cell how to build the SON protein.
SON is a helper for other genes
The SON protein is a “splicing helper.” It helps thousands of other genes get read correctly — especially ones the developing brain depends on. (The name SON is also why our foundation shines with sun imagery.)
In ZTTK, one copy can’t do its job
Everyone has two copies of SON. In ZTTK syndrome, a random change — called a de novo mutation, almost always new in the child rather than inherited — stops one copy from working. One working copy alone can’t make enough SON protein. Doctors call this haploinsufficiency: “half is not enough.”
Why it affects so much
Because SON helps so many other genes, not having enough affects the body in many ways — most of all the developing brain. This is also why every child with ZTTK is different: the same cause, a wide range of effects.
For the deeper molecular story — splicing, downstream genes, and current research — see The SON Gene.
How to Read the Genetic Test Report
Most families first meet ZTTK as a line on a genetic test report full of unfamiliar notation. Here’s what each part of that line actually means — using an example report.
Patient identifying information redacted for this example.
Gene: SON · Variant: c.5753_5756del (p.Val1918GlufsTer87)
Classification: Pathogenic · Inheritance: De novo · Zygosity: Heterozygous
The gene
SON is the gene’s name. Seeing “SON” here is what makes the diagnosis ZTTK syndrome.
The DNA change (c.)
“c.” describes the exact change in the gene’s DNA letters. This example — a deletion of 4 letters — is actually the most common ZTTK variant: roughly 1 in 4 diagnosed individuals share this exact change.
The protein effect (p.)
“p.” describes what the DNA change does to the SON protein — here, the instructions stop early, so no working protein is made from this copy.
Classification
Labs classify variants on a scale from “benign” to “pathogenic.” Pathogenic or “likely pathogenic” means the lab is confident this change causes the condition. If your report says “VUS” (variant of uncertain significance), ask about specialist review.
De novo
“New in your child.” The change was not inherited from either parent — nothing a parent did or could have prevented. This is the case for essentially all known ZTTK diagnoses — though someone who has ZTTK can pass the change to their own children.
This is a simplified example, not a real patient report. Your report may look different — your genetics team can walk you through it line by line, and our Newly Diagnosed guide lists the questions worth asking.
How ZTTK Can Affect the Body
ZTTK is a spectrum. These numbers come from the published research — but no child has every feature, and severity varies widely. Think of this as a map of what doctors watch for, not a prediction for any one child.
Brain & Development
100%
Every individual has some degree of developmental delay or intellectual disability; speech is delayed in 97%, and brain MRI differences are seen in 92%.
Muscles & Movement
83%
Low muscle tone (hypotonia) and delayed motor milestones are very common; skeletal differences like scoliosis or joint laxity occur in 83%.
Eyes & Vision
69%
Most commonly crossed eyes (strabismus) and farsightedness; regular eye exams are recommended.
Feeding & Growth
64%
Feeding difficulties, especially in infancy; about half of individuals have short stature.
Seizures
50–60%
Roughly half develop epilepsy, usually beginning between infancy and age 6. Seizures are manageable in many children.
Kidneys & Urinary
47%
Structural kidney differences are common enough that a yearly kidney ultrasound is standard care.
Heart
33%
Usually small holes between heart chambers (ASD/VSD) that are monitored and often close or are repairable.
Immune System
32%
Some individuals have low antibody levels (IgA/IgG) and get more infections; hearing differences occur in about 15%.
Frequencies from GeneReviews (2025) and Dingemans et al., Eur J Hum Genet (2022), the 52-person natural-history study.
Want every statistic in one place — variants, registry growth, research milestones? See ZTTK by the Numbers.
How ZTTK Is Diagnosed
ZTTK is a molecular diagnosis — it can only be confirmed by genetic testing. For most families the path looks like this:
Something prompts a look
Delayed milestones, low muscle tone, feeding trouble, or seizures lead a pediatrician to refer the family to genetics. ZTTK can’t be recognized from features alone — many conditions look similar early on.
Broad genetic sequencing
The standard test is exome or genome sequencing, ideally as a “trio” (child plus both parents). Because ZTTK’s features overlap with so many conditions, testing single genes one at a time is not recommended.
The lab classifies the variant
If a change in SON is found, the lab classifies it on a scale from benign to pathogenic using ACMG criteria. “Pathogenic” or “likely pathogenic” confirms the diagnosis.
ZTTK syndrome, confirmed
A confirmed diagnosis ends the diagnostic odyssey and starts a plan: specialist referrals, surveillance, school support — and a community that’s been exactly where you are.
Questions to ask your geneticist
- 1.Has the SON gene variant been confirmed by a certified clinical lab using ACMG variant classification criteria?
- 2.Is the variant classified as pathogenic or likely pathogenic?
- 3.Was parental testing done to confirm this is a de novo (new) mutation?
- 4.Should we pursue trio exome sequencing if not already done?
- 5.Are there known genotype-phenotype correlations for our child's specific variant?
- 6.What is the recommended surveillance for seizures, vision, kidneys, and cardiac function?
- 7.Can you connect us with the ZTTK natural history study or patient registry?
Got a “VUS” (variant of uncertain significance) instead of a clear answer? You're not alone — ask about specialist review, and reach out to us either way.
A Young Syndrome, Moving Fast
ZTTK was only named in 2016 — and the pace of progress since then is the hopeful part of this story.
2015
The first report.
A single patient with an unexplained developmental condition is described with a change in the SON gene (Zhu et al.).
2016
ZTTK syndrome gets its name.
Kim and colleagues describe 20 children with the same cause, defining a new syndrome; Takenouchi and colleagues independently confirm it. The syndrome is named for the four researchers: Zhu, Tokita, Takenouchi, Kim.
2022
The picture sharpens.
The largest study to date (52 individuals, Dingemans et al.) maps how ZTTK affects the body — the data behind most of the percentages on this page.
2024
The mouse model is published.
The first laboratory mouse carrying a SON change — developed in the Ahn lab — is published (JCI Insight), a crucial tool for testing future treatments.
2025
ZTTK enters the standard references.
GeneReviews — the reference clinicians use worldwide — publishes its first ZTTK chapter, citing the ZTTK SON-Shine Foundation’s own registry: ~500 known patients worldwide. Patient-derived stem-cell (iPSC) models, begun in 2023, are in use for drug-screening research.
Today
You can move this forward.
Every family that joins the patient census and every research dollar accelerates the next milestone.
Questions Families Ask
The questions we hear most — answered honestly, from the published research and from families who have lived them.
Is ZTTK inherited? Could it happen again in our family?
In essentially every known case, the SON gene change is de novo — brand new in the child, not inherited from either parent. Nothing a parent did or didn’t do caused it, and nothing could have prevented it. For those parents, the chance of it happening again in a future pregnancy is low — estimated around 1% — due to a possibility called germline mosaicism, and unaffected siblings are not expected to carry the change. One important nuance: ZTTK itself is heritable. A person who has ZTTK syndrome can pass the changed gene on, and each of their children would have a 50% (1 in 2) chance of inheriting it. A genetic counselor can walk through what this means for any family’s planning.
How many people have ZTTK syndrome?
About 79 individuals have been described in published medical studies, per GeneReviews’ 2025 literature review. But the ZTTK SON-Shine Foundation’s own registry and family network — the source GeneReviews itself cites — counts approximately 500 known individuals worldwide as of 2025. Because diagnosis requires advanced genetic testing that many families still can’t access, the true number is almost certainly higher.
Is there a cure or treatment?
There is no cure yet. Today’s care is symptom-based and genuinely effective at improving quality of life: therapies for development and communication, seizure medications, feeding support, and regular monitoring of vision, hearing, kidneys, and heart. Meanwhile the research foundation for future treatments is being built — a mouse model published in 2024, patient-derived stem-cell models, and a growing natural history study.
What will life look like for my child?
The honest answer is that ZTTK is a wide spectrum, and no percentage on this page predicts any one child. Every individual with ZTTK keeps learning and gaining skills at their own pace. Many children learn to walk, though usually later than typical; communication ranges from full speech to assistive devices that give non-speaking children a voice. Children and adults with ZTTK are part of our community — and their families are the best guides to what life really looks like.
Which specialists should be on our team?
Care is multidisciplinary. Most families work with a developmental pediatrician, neurologist, ophthalmologist, and audiologist, plus physical, occupational, and speech therapy. Standard surveillance includes a yearly kidney ultrasound, hearing check, and eye exam. Our Symptoms & Diagnosis and Clinical Care pages have details you can bring to your medical team.
What does SON have to do with sunshine?
SON is simply the gene’s scientific name — but our families decided it should stand for something brighter. That’s why we’re the SON-Shine Foundation, and why you’ll see suns everywhere we go: every child with ZTTK is somebody’s son or daughter, and somebody’s sunshine.
Sources
- GeneReviews: Zhu-Tokita-Takenouchi-Kim Syndrome (2025) — the current clinical reference, citing the Foundation's registry data.
- Kim et al., Am J Hum Genet (2016) — the paper that defined the syndrome.
- Dingemans et al., Eur J Hum Genet (2022) — the 52-person natural-history study behind most frequencies cited here.
- OMIM #617140 — the syndrome's catalog entry.
Content reviewed against GeneReviews (September 2025). Last updated September 2026.
Medical disclaimer
This page is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your child's medical team about specific clinical decisions.
You Are Not Alone
Hundreds of ZTTK families around the world have stood exactly where you're standing. The next step is easier together.